🇺🇸 FDA
Patent

US 11897969

Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 11897969 (Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury) held by The Regents of the University of California expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/39583